4.8 Article

The long noncoding RNA Wisper controls cardiac fibrosis and remodeling

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 9, 期 395, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aai9118

关键词

-

资金

  1. Swiss National Science Foundation, Bern, Switzerland [406340-128129, 31003A-163476]
  2. Ministry of Economy and Competitiveness, Spain [CB16/11/00483, RYC-2010-05797, PI15/01909]
  3. European Union (FIBRO-TARGETS consortium) [HEALTH-2013-602904]
  4. Netherlands Organization for Scientific Research (Vidi grant) [91714363]
  5. Netherlands Heart Foundation [Dekker 2014T105]
  6. Swiss National Science Foundation (SNF) [406340_128129, 31003A_163476] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

Long noncoding RNAs (lncRNAs) are emerging as powerful regulators of cardiac development and disease. However, our understanding of the importance of these molecules in cardiac fibrosis is limited. Using an integrated genomic screen, we identified Wisper (Wisp2 super-enhancer-associated RNA) as a cardiac fibroblast-enriched lncRNA that regulates cardiac fibrosis after injury. Wisper expression was correlated with cardiac fibrosis both in a murine model of myocardial infarction (MI) and in heart tissue from human patients suffering from aortic stenosis. Loss-of-function approaches in vitro using modified antisense oligonucleotides (ASOs) demonstrated that Wisper is a specific regulator of cardiac fibroblast proliferation, migration, and survival. Accordingly, ASO-mediated silencing of Wisper in vivo attenuated MI-induced fibrosis and cardiac dysfunction. Functionally, Wisper regulates cardiac fibroblast gene expression programs critical for cell identity, extracellular matrix deposition, proliferation, and survival. In addition, its association with TIA1-related protein allows it to control the expression of a profibrotic form of lysyl hydroxylase 2, implicated in collagen cross-linking and stabilization of the matrix. Together, our findings identify Wisper as a cardiac fibroblast-enriched super-enhancer-associated lncRNA that represents an attractive therapeutic target to reduce the pathological development of cardiac fibrosis in response to MI and prevent adverse remodeling in the damaged heart.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据